A BILL 
To amend title 35, United States Code, to prevent double 
patenting, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Terminating the Ex-
4
tension of Rights Misappropriated Act of 2019’’ or the 
5
‘‘Term Act of 2019’’. 
6
SEC. 2. PREVENTION OF DOUBLE PATENTING. 
7
(a) IN GENERAL.—Section 253 of title 35, United 
8
States Code, is amended by adding at the end the fol-
9
lowing: 
10
04:24 Jun 14, 2019
H3199
2 
•HR 3199 IH
‘‘(c) DISCLAIMERS OF DRUG PATENT TERM.— 
1
‘‘(1) IN GENERAL.—Except as provided in para-
2
graph (2), in a proceeding challenging the validity of 
3
patents under section 505(c) of the Federal Food, 
4
Drug, and Cosmetic Act (21 U.S.C. 355(c)) with re-
5
spect to a drug, under section 351(l) of the Public 
6
Health Service Act (42 U.S.C. 262(l)) with respect 
7
to a biological product, or a Federal district court 
8
proceeding involving patents that are the subject of 
9
an action under section 271(e)(2), the patentee shall 
10
be presumed to have disclaimed the patent term for 
11
each of the listed patents after the date on which the 
12
term of the first patent expires, subject to the excep-
13
tions provided for in subsection (2). 
14
‘‘(2) DEMONSTRATION
OF
DISTINCT
INVEN-
15
TIONS.—If a patentee demonstrates by a preponder-
16
ance of the evidence that certain patents described 
17
in paragraph (1) cover patentably distinct inventions 
18
from the invention claimed in the first such patent 
19
to expire, no part of the term of any such patent 
20
shall be presumed to have been disclaimed, and all 
21
patent term extensions granted by the United States 
22
Patent and Trademark Office shall be respected, un-
23
less and to the extent the patentee expressly dis-
24
04:24 Jun 14, 2019
H3199
3 
•HR 3199 IH
claims, in writing, the patent term for each such 
1
patent.’’. 
2
(b) USPTO REVIEW.— 
3
(1) DEFINITIONS.—In this subsection— 
4
(A) the term ‘‘Office’’ means the United 
5
States Patent and Trademark Office; and 
6
(B) the term ‘‘Director’’ means the Under 
7
Secretary of Commerce for Intellectual Property 
8
and Director of the Office. 
9
(2) REVIEW.—The Director shall conduct a 
10
comprehensive review of the patent examination pro-
11
cedures of the Office to determine whether the Of-
12
fice— 
13
(A) is using best examination practices, 
14
guidance, and procedures to avoid the issuance 
15
of patents relating to the same drug, or biologi-
16
cal product, that are not patentably distinct 
17
from one another, and not subject to an appro-
18
priate disclaimer of patent term; and 
19
(B) should develop and implement new 
20
practices, guidance, or procedures to— 
21
(i) improve examination of patent ap-
22
plications relating to the same drug or bio-
23
logical product; and 
24
04:24 Jun 14, 2019
H3199
4 
•HR 3199 IH
(ii) reduce the improper issuance of 
1
patents that improperly extend the term of 
2
exclusivity afforded a new drug or biologi-
3
cal product. 
4
(3) REPORT.—Not later than 1 year after the 
5
date of enactment of this Act, the Director shall 
6
submit to the Committee on the Judiciary of the 
7
House of Representatives a report that contains— 
8
(A) the findings from the review conducted 
9
under paragraph (2); and 
10
(B) any recommendations of the Director 
11
with respect to the review conducted under 
12
paragraph (2). 
13
Æ 
04:24 Jun 14, 2019
H3199
